Skip to main content

Advertisement

SpringerLink
Log in

Bowel Perforation After Treatment with Sorafenib: A Case Report and Review of Literature

  • Case Report
  • Published:
Journal of Gastrointestinal Cancer Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Reference

  1. FDA Approval for Sorafenib Tosylate available from http://www.cancer.gov/cancertopics/druginfo/fda-sorafenib-tosylate accessed on 12/28/2014.

  2. Hapani S, Chu D, Wu S. Risk of gastrointestinal perforation in patients with cancer treated with bevacizumab: a meta-analysis. Lancet Oncol. 2009;10(6):559–68.

    Article  CAS  PubMed  Google Scholar 

  3. Qi WX, Sun YJ, Tang LN, Shen Z, Yao Y. Risk of gastrointestinal perforation in cancer patients treated with vascular endothelial growth factor receptor tyrosine kinase inhibitors: a systematic review and meta-analysis. Crit Rev Oncol Hematol. 2014;89(3):394–403.

    Article  PubMed  Google Scholar 

  4. Adnane L, Trail PA, Taylor I, Wilhelm SM. Sorafenib (BAY 43–9006, Nexavar), a dual-action inhibitor that targets RAF/MEK/ERK pathway in tumor cells and tyrosine kinases VEGFR/PDGFR in tumor vasculature. Methods Enzymol. 2006;407:597–612.

    Article  CAS  PubMed  Google Scholar 

  5. Bamias A, Pignata S, Pujade-Lauraine E. Angiogenesis: a promising therapeutic target for ovarian cancer. Crit Rev Oncol Hematol. 2012;84(3):314–26.

    Article  CAS  PubMed  Google Scholar 

  6. Wu S, Keresztes RS. Antiangiogenic agents for the treatment of nonsmall cell lung cancer: characterizing the molecular basis for serious adverse events. Cancer Invest. 2011;29(7):460–71.

    CAS  PubMed  Google Scholar 

  7. Eng FC, Easson AM, Szentgyorgyi E, Knox JJ. Sorafenib and surgical complications: a case report of adverse reaction to sorafenib during treatment for renal cell carcinoma. Eur J Surg Oncol. 2009;35(2):219–21.

    Article  CAS  PubMed  Google Scholar 

  8. Maki RG, D'Adamo DR, Keohan ML, Saulle M, Schuetze SM, Undevia SD, et al. Phase II study of sorafenib in patients with metastatic or recurrent sarcomas. J Clin Oncol. 2009;27(19):3133–40.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Ott PA, Hamilton A, Min C, Safarzadeh-Amiri S, Goldberg L, Yoon J, et al. A phase II trial of sorafenib in metastatic melanoma with tissue correlates. PLoS One. 2010;5(12), e15588.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Barney BM, Markovic SN, Laack NN, Miller RC, Sarkaria JN, Macdonald OK, et al. Increased bowel toxicity in patients treated with a vascular endothelial growth factor inhibitor (VEGFI) after stereotactic body radiation therapy (SBRT). Int J Radiat Oncol Biol Phys. 2013;87(1):73–80.

    Article  CAS  PubMed  Google Scholar 

  11. Kobayashi H, Ashikari A, Namitome R, Yagi Y, Kohno Y, Nishiyama T, et al. [Two cases of bowel perforation in patients with metastatic renal cancer treated with a molecularly targeted drug]. Nihon Hinyokika Gakkai zasshi Jpn J Urol. 2012;103(5):660–4.

  12. Inoue T, Kinoshita H, Komai Y, Kawabata T, Kawa G, Uemura Y, et al. Two cases of gastrointestinal perforation after radiotherapy in patients receiving tyrosine kinase inhibitor for advanced renal cell carcinoma. World J Surg Oncol. 2012;10:167.

    Article  PubMed  PubMed Central  Google Scholar 

  13. Park SG, Chung CH, Park CY. Colon perforation during sorafenib therapy for advanced hepatocelluar carcinoma. A case report. Tumori. 2011;97(6):794–9.

    CAS  PubMed  Google Scholar 

  14. Walraven M, Witteveen PO, Lolkema MP, van Hillegersberg R, Voest EE, Verheul HM. Antiangiogenic tyrosine kinase inhibition related gastrointestinal perforations: a case report and literature review. Angiogenesis. 2011;14(2):135–41.

    Article  PubMed  Google Scholar 

  15. Frieling T, Heise J, Wassilew SW. Multiple colon ulcerations, perforation and death during treatment of malignant melanoma with sorafenib. Deutsche medizinische Wochenschrift (1946). 2009;134(28–29):e1-2, 1464–6.

  16. Peters NA, Richel DJ, Verhoeff JJ, Stalpers LJ. Bowel perforation after radiotherapy in a patient receiving sorafenib. J Clin Oncol. 2008;26(14):2405–6.

    Article  PubMed  Google Scholar 

Download references

Conflict of Interests

The authors declare that they have no competing interests.

Funding

None

Author information

Authors and Affiliations

  1. Department of Internal Medicine, Creighton University School of Medicine, 601 N. 30th Street Suite 5850, Omaha, NE, 68131, USA

    Shadi Hamdeh, Smrity Upadhyay, Nabin Khanal & Stephen Lanspa

Authors
  1. Shadi Hamdeh
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Smrity Upadhyay
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Nabin Khanal
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Stephen Lanspa
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Shadi Hamdeh.

Additional information

Shadi Hamdeh and Smrity Upadhyay contributed equally to this work.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Hamdeh, S., Upadhyay, S., Khanal, N. et al. Bowel Perforation After Treatment with Sorafenib: A Case Report and Review of Literature. J Gastrointest Canc 47, 420–422 (2016). https://doi.org/10.1007/s12029-015-9752-x

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12029-015-9752-x

Keywords

Search

Navigation